The Clock Runs Down on Two Federal Deadlines That Will Define Cannabis for Years

The Clock Runs Down on Two Federal Deadlines That Will Define Cannabis for Years

Cannabis policy in the United States is being shaped this summer not by a single dramatic vote but by two ticking clocks, and this week pushed both closer to zero. One could finally move marijuana off Schedule I after more than half a century. The other could erase a multibillion-dollar hemp industry almost overnight. For consumers and operators alike, the next several weeks will matter more than any in recent memory.

The first clock is rescheduling. The Drug Enforcement Administration is set to open an expedited administrative hearing on June 29 to weigh moving all marijuana from Schedule I to Schedule III of the Controlled Substances Act, a process formally laid out in the agency's Federal Register notice. The hearing follows the Justice Department's April order that immediately placed FDA-approved and state-licensed medical marijuana products in Schedule III while leaving the broader question of the whole plant to this summer's proceeding. The run-up dominated the week, with state-licensed medical operators facing a June 22 registration deadline and the DEA already conducting on-site inspections at businesses that sought federal protection under the interim order.

What does rescheduling actually change at the dispensary counter? Less than many consumers assume, at least at first. Schedule III would not make recreational cannabis federally legal, and it would not automatically open interstate commerce. What it would do is remove Section 280E of the tax code, the provision that bars cannabis businesses from deducting ordinary expenses and effectively taxes many of them at punitive rates. For operators, that single change could be the difference between losing money and turning a profit — which is exactly why the industry is watching the June 29 hearing with such intensity, and why the difference between rescheduling FDA-approved products and rescheduling the entire plant is worth billions.

While rescheduling could relieve the industry, the second clock threatens to crush a parallel one. Under Section 781 of the 2026 appropriations law, the federal definition of hemp is set to tighten dramatically on November 12, shifting to a total-THC standard and capping finished hemp products at just 0.4 milligrams of THC per container. Industry analysts estimate the change would render roughly 95% of existing hemp-derived cannabinoid products federally unlawful, upending a market that trade groups value at around $28 billion and 300,000-plus jobs. For consumers, that is the delta-8 gummy at the gas station, the THC seltzer at the grocery store, and much of the CBD aisle — potentially gone unless Congress acts.

That "unless" is where the week's legislative maneuvering came in. Lawmakers are scrambling to soften or delay the hemp hammer through several vehicles, including a bipartisan Hemp Planting Predictability Act that would push the ban's effective date back two years to November 2028, and a separate proposal from Representative Andy Barr to legalize and tightly regulate consumable hemp products rather than prohibit them outright, rewriting the federal hemp definition for a market it acknowledges already exceeds $30 billion. The practical question for operators is brutal: build inventory and hope for a delay, or wind down product lines before November and absorb the loss now.

The policy churn was not confined to Washington. Internationally, New Zealand moved in the opposite direction from the United States, raising the legal THC limit in hemp from 0.35% to 1% — a reminder that the global trend on hemp is far from settled and that other markets see economic opportunity where U.S. lawmakers see risk. In Canada, regulators kept the focus on rules of a different kind. Health Canada's consultation on potential changes to the country's industrial hemp regulations remains open for public input until June 30, and the agency ordered an Ontario cannabis retailer to remove a colorful mural for running afoul of strict promotion rules — a small case that captures how tightly Canada still polices cannabis marketing.

There was a notable courtroom development too. The U.S. Supreme Court barred the government from broadly restricting the gun rights of casual drug users in a case involving a Texas man who occasionally consumed marijuana. The ruling legalizes nothing, but it chips at one of the everyday legal disabilities cannabis consumers have lived under — and signals that the collision between federal prohibition and individual rights is increasingly being settled in court.

For everyone in this industry, the takeaway from the week is the same: certainty is not coming on a comfortable timeline. A medical operator who registers with the DEA and waits for the June 29 hearing, a hemp-beverage brand staring at a November deadline, and a consumer wondering whether their favorite gummy will still be legal by Thanksgiving are all standing in the same uncomfortable place. The decisions made in the next four months — in a DEA hearing room and on the floor of Congress — will determine whether 2026 is remembered as the year cannabis policy finally rationalized, or the year it fractured into something even messier.